Navigation Links
Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
Date:10/25/2012

An interdisciplinary team of researchers has dissected a case of synergy in drug-resistant chronic myeloid leukemia to understand the mechanism by which two drugs, danusertib and bosutinib, work together to overcome resistance in the BCR-ABL gatekeeper mutation-specific disease. The team includes a researcher at Moffitt Cancer Center and colleagues at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Austria and the Massachusetts Institute of Technology. The goal is to address an unmet medical need because this BCR-ABL mutation confers resistance to all currently approved kinase inhibitors for chronic myeloid leukemia.

The study appeared in the Sept. 30 online version of Nature Chemical Biology.

"Treatment of chronic myeloid leukemia rapidly improved after the introduction of the first BCR-ABL inhibitor, Gleevec (imatinib)," said study co-author Uwe Rix, Ph.D., an assistant member of the Moffitt's Drug Discovery Department and Experimental Therapeutics Program. "However, it soon became apparent that a broad spectrum of possible resistance mechanisms necessitated second- and third-generation BCR-ABL inhibitors. Although these are mostly very successful, none of the currently approved options has been effective in patients with chronic myeloid leukemia who harbor the BCR-ABL gatekeeper mutation."

The researchers investigated the molecular mechanisms and logic underlying the synergistic interaction between danusertib and bosutinib, which is specific for BCR-ABL gatekeeper mutation-transformed cells. They applied a novel systems pharmacology approach involving a combination of different proteomics and gene expression profiling methods.

"We found previously unappreciated features of both agents," Rix said. "The synergy did not correlate with direct inhibition of BCR-ABL. Instead, our observations converged on the downstream MAPK signaling cascade as the predominantly affected pathway in
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... iFitDress.com, a well-known wedding dress manufacturer and retailer, has unveiled ... from this, it has announced that all of them are ... of its old and new clients may now access the ... “We are pleased to release the new collection of satin ... of amazing items. It is true that our satin bridal ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... discovered a chemical alteration in a single human gene ... studies, could give doctors a simple blood test to ... The discovery, described online in The American Journal ... involved in the function of the brain,s response to ... might otherwise be an unremarkable reaction to the strain ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps ... that he cured his condition with the use of this ... of his experience. , He claimed that he was ... just 4 days. Since his method turned out being so ... around the world. , The Nasal Polyps Treatment Miracle ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... the US Food and Drug Administration gave its approval ... in the treatment of chronic Hepatitis B// (HBV). Clinical studies ... effects and is usually well tolerated. ,Hepatitis B ... 70,000 Americans every year. It is a serious illness and ...
... workplace cafeterias and vending machines, to understand the nature of ... in the levels of obesity, this is certainly called for, ... diseases. ,The Ministry of Health will keep ... next two years to ascertain the types of food enabled ...
... vaccine are underway in Mozambique, certainly not a farfetched goal ... The production// of the vaccine is estimated at about $60-million. ... addressing a gathering of health officials said 'We think the ... tests in Manhica (north of the capital Maputo) are effective. ...
... boy died of dengue fever here Wednesday, taking the toll ... as officials maintained that the number of cases had dropped ... Pradesh, died at the All India Institute of Medical Sciences ... in a critical condition. , ,"His condition was deteriorating ...
... light on the alarming trend among teenage girls taking to smoking//, ... to dispel the myth that smoking helps in controlling weight. , ... much the same way as their peers who do not smoke. ... which deserves to be puffed out. , ,Dr. Louise Pilote, ...
... dose of folic acid every day could have better chance of ... a form of vitamin B is used in our bodies to ... her body before she is pregnant, it can help prevent major ... latest study involving more than 18,000 women for the first time ...
Cached Medicine News:Health News:13-Year-Old Boy Is Latest Dengue Victim; Delhi Toll 47 2Health News:Folic Acid Supplements Could Help Conception 2
(Date:7/29/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... specific pathogens that cause serious infections and diseases, announced ... in the Company,s stock, the NYSE MKT (the "Exchange") ... practice. The Company stated that its policy is not ... Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE ...
(Date:7/29/2014)... Numotion,s Board of Directors has announced that as ... the company,s new Chief Executive Officer. Swinford ... where he worked primarily for GE Healthcare Services, running businesses ... billion. His most recent position was as President and CEO ... thrilled to join Numotion," said Mike Swinford . "I ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Orthopedic Trauma Fixation Devices ... Industry Analysis 2014 - 2020", the global orthopedic trauma ... in 2014 and is expected to grow at a ... an estimated value of USD 9.3 billion in 2020. ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2Numotion Names Mike Swinford CEO 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
0.12 1x2 tips on a 2.5mm platform; Stainless Steel Tip; 32mm shaft; Titanium Handle....
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Straight Shafts with 0.12mm 1X2 Teeth With 5mm Tying Platform; In Titanium...
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium....
Medicine Products: